aluates Reports

$ 0.0

Automative

Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2026

Published Date: 2026-03-11

Report Code: QYRE-Auto-3O18093

Global GLP 1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2024

BUY CHAPTERS

Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2026

Code: QYRE-Auto-3O18093

Report

2026-03-11

Pages:94

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Novo Nordisk

Eli Lilly

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market

The global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.

GLP-1 agonists are a class of pharmaceutical agents used to treat both type 2 diabetes mellitus and obesity,including semaglutide,liraglutide,tirzepatide,and others,which can stimulate GLP-1 receptors,leading to increased insulin secretion in response to meals,decreased glucagon release,and slowed gastric emptying.While GLP-1 agonists can also promote weight loss by enhancing feelings of fullness and decreasing appetite.

The North American market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity in Hospital and Clinic is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of GLP-1 Agonists for the Treatment of both Diabetes and Obesity include Novo Nordisk, Eli Lilly, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding GLP-1 Agonists for the Treatment of both Diabetes and Obesity. The GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist GLP-1 Agonists for the Treatment of both Diabetes and Obesity manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Report

Report Metric	Details
Report Name	GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market
Segment by Type	Semaglutide Liraglutide Tirzepatide
Segment by Application	Hospital and Clinic Retail Pharmacies Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novo Nordisk, Eli Lilly
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for GLP-1 Agonists for the Treatment of both Diabetes and Obesity companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market report?

Ans: The main players in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market are Novo Nordisk, Eli Lilly

What are the Application segmentation covered in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market report?

Ans: The Applications covered in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market report are Hospital and Clinic, Retail Pharmacies, Other

What are the Type segmentation covered in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market report?

Ans: The Types covered in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market report are Semaglutide, Liraglutide, Tirzepatide

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Semaglutide

1.2.3 Liraglutide

1.2.4 Tirzepatide

1.3 Market by Application

1.3.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Hospital and Clinic

1.3.3 Retail Pharmacies

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Perspective (2021–2032)

2.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Growth Trends by Region

2.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Region (2021–2026)

2.2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Region (2027–2032)

2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Dynamics

2.3.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Trends

2.3.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers

2.3.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Challenges

2.3.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Revenue

3.1.1 Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Revenue (2021–2026)

3.1.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Players (2021–2026)

3.2 Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue

3.4 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Concentration Ratio

3.4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue in 2025

3.5 Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity Head Offices and Areas Served

3.6 Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Products and Applications

3.7 Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Breakdown Data by Type

4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Type (2021–2026)

4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Type (2027–2032)

5 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Breakdown Data by Application

5.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Application (2021–2026)

5.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)

6.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021–2026)

6.4 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)

7.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021–2026)

7.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)

8.2 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021–2026)

8.4 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)

9.2 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021–2026)

9.4 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)

10.2 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021–2026)

10.4 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novo Nordisk

11.1.1 Novo Nordisk Company Details

11.1.2 Novo Nordisk Business Overview

11.1.3 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Introduction

11.1.4 Novo Nordisk Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021–2026)

11.1.5 Novo Nordisk Recent Development

11.2 Eli Lilly

11.2.1 Eli Lilly Company Details

11.2.2 Eli Lilly Business Overview

11.2.3 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Introduction

11.2.4 Eli Lilly Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021–2026)

11.2.5 Eli Lilly Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Novo Nordisk

Eli Lilly

List of Tables

Table 1. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Semaglutide

Table 3. Key Players of Liraglutide

Table 4. Key Players of Tirzepatide

Table 5. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 6. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (US$ Million), 2021–2026

Table 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2021–2026)

Table 9. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Region (US$ Million), 2027–2032

Table 10. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2027–2032)

Table 11. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Trends

Table 12. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers

Table 13. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Challenges

Table 14. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints

Table 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Players (US$ Million), 2021–2026

Table 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Players (2021–2026)

Table 17. Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Tier (Tier 1, Tier 2, and Tier 3), based on GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, 2025

Table 18. Ranking of Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Companies by Revenue (US$ Million) in 2025

Table 19. Global 5 Largest Players Market Share by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (CR5 and HHI), 2021–2026

Table 20. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Headquarters and Area Served

Table 21. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Products and Applications

Table 22. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Date of General Availability (GA)

Table 23. Mergers and Acquisitions, Expansion Plans

Table 24. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (US$ Million), 2021–2026

Table 25. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2021–2026)

Table 26. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Type (US$ Million), 2027–2032

Table 27. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2027–2032)

Table 28. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (US$ Million), 2021–2026

Table 29. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2021–2026)

Table 30. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Application (US$ Million), 2027–2032

Table 31. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2027–2032)

Table 32. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 33. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2021–2026

Table 34. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2027–2032

Table 35. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 36. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2021–2026

Table 37. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2027–2032

Table 38. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 39. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (US$ Million), 2021–2026

Table 40. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (US$ Million), 2027–2032

Table 41. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 42. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2021–2026

Table 43. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2027–2032

Table 44. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 45. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2021–2026

Table 46. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2027–2032

Table 47. Novo Nordisk Company Details

Table 48. Novo Nordisk Business Overview

Table 49. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product

Table 50. Novo Nordisk Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (US$ Million), 2021–2026

Table 51. Novo Nordisk Recent Development

Table 52. Eli Lilly Company Details

Table 53. Eli Lilly Business Overview

Table 54. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product

Table 55. Eli Lilly Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (US$ Million), 2021–2026

Table 56. Eli Lilly Recent Development

Table 57. Research Programs/Design for This Report

Table 58. Key Data Information from Secondary Sources

Table 59. Key Data Information from Primary Sources

Table 60. Authors List of This Report

List of Figures

Figure 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Picture

Figure 2. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type: 2025 vs 2032

Figure 4. Semaglutide Features

Figure 5. Liraglutide Features

Figure 6. Tirzepatide Features

Figure 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (US$ Million), 2021–2032

Figure 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application: 2025 vs 2032

Figure 9. Hospital and Clinic Case Studies

Figure 10. Retail Pharmacies Case Studies

Figure 11. Other Case Studies

Figure 12. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Report Years Considered

Figure 13. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 14. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region: 2025 vs 2032

Figure 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Players in 2025

Figure 17. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 18. The Top 10 and 5 Players Market Share by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue in 2025

Figure 19. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 20. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021–2032)

Figure 21. United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021–2032)

Figure 25. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. U.K. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Ireland GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2021–2032)

Figure 33. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Australia & New Zealand GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021–2032)

Figure 41. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021–2032)

Figure 45. Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Novo Nordisk Revenue Growth Rate in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021–2026)

Figure 49. Eli Lilly Revenue Growth Rate in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021–2026)

Figure 50. Bottom-up and Top-down Approaches for This Report

Figure 51. Data Triangulation

Figure 52. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global GLP 1 Agonists for Obesity Market Research Report 2024

Global Glucagon Like Peptide 1 GLP 1 Agonists Market Research Report 2025

Global Antidiabetic Glucagon like Peptide 1 Agonists Market Research Report 2025

Global GLP 1 Agonist Injection Market Research Report 2024

GLP Analogs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oral GLP 1 Agonist Market Research Report 2024

Global Liraglutide for The Treatment of Diabetes and Obesity Market Research Report 2024

Global GLP 1 Weight Loss Pill Market Research Report 2024

Global Glucagon like peptide 1 GLP 1 based Therapies Market Research Report 2025

Global GLP 1 Receptor Antagonist Market Research Report 2024

GLP 1 for Weight Loss Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1RA based Therapy for Obesity Market Research Report 2024

Global GLP 1 Drugs Market Research Report 2024

Global GLP 1 Weight Loss Injection Market Research Report 2024

Global GLP 1 Weight Loss Drug Market Research Report 2024

Global Semaglutide Preparations Market Research Report 2024

Global Semaglutide Injection Market Research Report 2024

GLP 1 Analogues Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1RA Therapy Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions